Back to top
more

Intercept Pharmaceuticals, Inc. (ICPT)

(Delayed Data from NSDQ)

$89.92 USD

89.92
705,568

+1.71 (1.94%)

Updated May 3, 2019 04:00 PM ET

After-Market: $89.98 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Intercept Pharmaceuticals (ICPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Intercept (ICPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strength Seen in Celldex (CLDX): Can Its 7.1% Jump Turn into More Strength?

by Zacks Equity Research

Celldex (CLDX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Intercept (ICPT) Moves 15.0% Higher: Will This Strength Last?

by Zacks Equity Research

Intercept (ICPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Intercept (ICPT) Stock Down on FDA Committee Update on NDA

by Zacks Equity Research

Intercept (ICPT) declines on news of a GIDAC meeting to discuss the NDA for the OCA for NASH in May.

Heres Why Intercept (ICPT) Stock is Up 28.7% in 3 Months

by Zacks Equity Research

Intercept (ICPT) gains 28.7% in the past 3 months on NDA's acceptance for NASH treatment and Ocaliva's performance.

Intercept (ICPT) Q4 Earnings Beat, Ocaliva Sales Increase

by Zacks Equity Research

Intercept (ICPT) posts a narrower loss in Q4 due to higher revenues.

Intercept Pharmaceuticals (ICPT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Intercept (ICPT) delivered earnings and revenue surprises of 20.75% and 0.42%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Novavax (NVAX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Novavax (NVAX) delivered earnings and revenue surprises of -147.83% and 5.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Immunocore (IMCR) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On Immunocore's (IMCR) Q4 earnings call, investors will likely focus on the sales figure of Kimmtrak - its first-line treatment for metastatic uveal melanoma - and updates on its pipeline candidates.

Will Akoya Biosciences (AKYA) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Akoya (AKYA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Intercept Pharmaceuticals (ICPT) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

by Zacks Equity Research

Intercept (ICPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Does Intercept (ICPT) Have the Potential to Rally 52.08% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 52.1% in Intercept (ICPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Intercept's (ICPT) NDA for NASH Treatment Accepted By FDA

by Zacks Equity Research

Intercept's (ICPT) new drug application (NDA) for obeticholic acid (OCA) for the treatment of nonalcoholic steatohepatitis gets accepted by the regulatory body in the United States.

Intercept (ICPT) Gains 12.4% in the Past Six Months: Here's Why

by Zacks Equity Research

Intercept (ICPT) gains 12% in the last six months on Ocaliva's positive performance and encouraging pipeline progress.

Chemomab (CMMB) Mid-Stage Study for NASH Meets Primary Goal

by Zacks Equity Research

Chemomab's (CMMB) phase II study evaluating CM-101 in NASH patients met its primary endpoint of safety and tolerability.

Madrigal (MDGL) Soars as Resmetirom Meets Goal in NASH Study

by Zacks Equity Research

Madrigal's (MDGL) phase III MAESTRO-NASH study evaluating resmetirom for treating nonalcoholic steatohepatitis and liver fibrosis meets both primary endpoints. Stock rises.

Why Is Intercept (ICPT) Down 3.9% Since Last Earnings Report?

by Zacks Equity Research

Intercept (ICPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Intercept (ICPT) Q3 Earnings Miss, Sales Beat, View Raised

by Zacks Equity Research

Intercept (ICPT) posts a wider loss in Q3 due to a loss on extinguishment of debt but beats on sales. Management increases annual sales guidance.

Intercept Pharmaceuticals (ICPT) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Intercept (ICPT) delivered earnings and revenue surprises of -159.49% and 2.62%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Sarepta Therapeutics (SRPT) Q3 Earnings Expected to Decline

by Zacks Equity Research

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Implied Volatility Surging for Intercept Pharmaceuticals (ICPT) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Intercept Pharmaceuticals (ICPT) stock based on the movements in the options market lately.

Biotech Stock Roundup: ICPT, KALV Down on Study Data, VIR Up on Contract Win & More

by Zacks Equity Research

Regulatory and pipeline updates from ICPT and KALV are the key highlights from the biotech sector during the past week.

Intercept (ICPT) Stock Gains 13% in 3 Months: Here's Why

by Zacks Equity Research

Intercept (ICPT) gains 13% in the past three months on positive regulatory and pipeline updates.

Regeneron (REGN)/ Alnylam Report Promising Data from NASH Study

by Zacks Equity Research

Regeneron (REGN) and its partner Alnylam announce promising data from its ongoing phase I study evaluating ALN-HSD in healthy adults and NASH patients.

Altimmune's (ALT) Data From NASH Study Fail to Impress Investors

by Zacks Equity Research

Altimmune (ALT) reports positive top-line results from its 12-week phase I study evaluating pemvidutide in patients with non-alcoholic fatty liver disease. The results fail to impress investors.